Bunyaviral Cap-Snatching Endonuclease Activity and Inhibition with Baloxavir-like Inhibitors in the Context of Full-Length L Proteins
Viruses · 2025
DOI: 10.3390/v17030420 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Arlo J Loutan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2E1, Canada. Hauptthemen laut MEDLINE: Endonucleases, Antiviral Agents, Viral Proteins, Triazines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, NIH.
Abstract (Originalsprache)
The Bunyavirales order includes a range of zoonotic viruses, which can cause severe disease in humans. The viral replication machinery is a logical target for the development of direct-acting antivirals. Inhibition of the cap-snatching endonuclease activity of related influenza viruses provides a proof of concept. Using the influenza B virus (IBV) RNA-dependent RNA polymerase complex as a benchmark, we conducted a comparative analysis of endonuclease activities of recombinant full-length bunyaviral L proteins using gel-based assays. The IBV complex demonstrates specific endonucleolytic cleavage and a clear preference for capped substrates. In contrast, severe fever with thrombocytopenia syndrome, Sin Nombre, and Hantaan virus L proteins readily cleave capped and uncapped RNAs to a broader spectrum of RNA fragments. Active site mutants further help to control for the potential of contaminating nucleases, exonuclease activity, and RNA hydrolysis. The influenza cap-snatching inhibitor baloxavir and derivatives have been used to validate this approach. In conclusion, the results of this study demonstrate the importance of assays with single nucleotide resolution and the use of full-length L proteins as a valuable experimental tool to identify selective endonuclease inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Microbiology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2E1, Canada.
- Calibr-Skaggs Institute for Innovation Medicines at Scripps Research, La Jolla, CA 92037, USA.
ORCID-Profile: Arlo J Loutan
Förderung
- NIAID NIH HHS
- NIH HHS
- NIH
- SPP-ARC (Striving for Pandemic Preparedness—The Alberta Research Consortium)
Zitieren
APA
Loutan, A. J., Yang, B., Connolly, G., Montoya, A., Smiley, R. J., Chatterjee, A. K., & Götte, M. (2025). Bunyaviral Cap-Snatching Endonuclease Activity and Inhibition with Baloxavir-like Inhibitors in the Context of Full-Length L Proteins. Viruses. https://doi.org/10.3390/v17030420
Vancouver
Loutan AJ, Yang B, Connolly G, Montoya A, Smiley RJ, Chatterjee AK, et al. Bunyaviral Cap-Snatching Endonuclease Activity and Inhibition with Baloxavir-like Inhibitors in the Context of Full-Length L Proteins. Viruses. 2025. doi:10.3390/v17030420
BibTeX
@article{Loutan2025,
author = {Loutan, Arlo J and Yang, Baiuyan and Connolly, Gabrielle and Montoya, Adam and Smiley, Robert J and Chatterjee, Arnab K and Götte, Matthias},
title = {Bunyaviral Cap-Snatching Endonuclease Activity and Inhibition with Baloxavir-like Inhibitors in the Context of Full-Length L Proteins},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17030420}
}
EUVIMED